Skip to main content

Table 3 Outcome of VL Test by ART Cohort Year (n = 53,074 patients)a

From: Expanded access to viral load testing and use of second line regimens in Haiti: time trends from 2010–2017

 

2010 ART Cohort

2011 ART Cohort

2012 ART Cohort

2013 ART Cohort

2014 ART Cohort

2015 ART Cohort

2016 ART Cohort

Total

Total # of patients

3914

5863

8641

10,812

11,629

10,325

1890

53,074

 % with no test

56.6%

55.6%

57.5%

58.0%

54.0%

52.7%

48.3%

55.3%

 % suppressed

29.4%

30.1%

28.4%

28.2%

32.4%

32.8%

36.3%

30.6%

 % unsuppresseda

14.0%

14.3%

14.1%

13.8%

13.6%

14.5%

15.4%

14.1%

Among patients with initial unsuppressed result

 

 # unsuppressed

549

841

1213

1494

1588

1492

291

7468

 % re-suppressed

16.4%

12.0%

13.9%

12.6%

11.6%

10.9%

10.3%

12.4%

 % unsuppressed followed by no test

50.6%

55.8%

57.3%

57.5%

61.2%

64.6%

70.1%

59.5%

 % confirmed failure

33.0%

32.2%

28.8%

29.9%

27.2%

24.5%

19.6%

28.1%

Among patients with confirmed failure

 

 # confirmed failure

181

271

349

447

431

366

57

2102

 % with strong adherence

47.0%

46.1%

47.9%

43.8%

43.9%

40.7%

49.1%

44.7%

 % with weak adherence

53.0%

53.9%

52.1%

56.2%

56.1%

59.3%

50.9%

55.3%

  1. a Includes ART patients with at least 18 months of follow-up time (see Table 1 for characteristics of 53,074 ART patients). VL status is based on up to two most recent tests, and the unsuppressed group includes patients who had a single test with unsuppressed result, as well as patients who had two tests with an unsuppressed result on one or both tests